Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 4/20 | 0.56 |
| ▸ | CDK8 | P49336 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
| ▸ | EIF4E | P06730 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581108 | 0.91 | CCNC (0.52) | CCNCCDK8NPC1RAB9AMKNK1 | |
| SCHEMBL18024246 | 0.89 | CCNC (0.55) | CCNCCDK8NPC1RAB9AMKNK1 | |
| SCHEMBL4581564 | 0.88 | ALDH1A1 (0.53) | CCNCCDK8NPC1RAB9AALDH1A1 | |
| SCHEMBL4581031 | 0.88 | CCNC (0.43) | CCNCCDK8NPC1RAB9AMKNK1 | |
| SCHEMBL18024514 | 0.87 | EIF4E (0.49) | CCNCCDK8NPC1RAB9AMKNK1 | |
| SCHEMBL4580840 | 0.85 | GRIN2B (0.54) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18024140 | 0.81 | CCNC (0.45) | CCNCCDK8RAB9AMKNK1ALDH1A1 | |
| SCHEMBL18024141 | 0.78 | KDM4E (0.44) | NPC1RAB9AMKNK1ALDH1A1KDM4E | |
| SCHEMBL15742914 | 0.75 | CCNC (0.72) | CCNCCDK8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5263350 | 0.74 | CCNC (0.64) | CCNCCDK8MKNK1MKNK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | disclosed |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | disclosed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885NPC1 916/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885NPC1 916/4885 |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | CCNC 3798/4885CDK8 3244/4885NPC1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.